The model predicts that a smaller PB-CD34+ cell count was needed to reach 2 × 106 and 5 × 106 AP-CD34+ cells/kg with a probability of 0.90 in patients with neuroblastoma tumor type than in those with other tumor types (Fig. 5). This evidence concerns the gene CD34 and neoplasm.